標題: Titlebook: Computational Modeling of Drugs Against Alzheimer’s Disease; Kunal Roy Book 2023Latest edition The Editor(s) (if applicable) and The Autho [打印本頁] 作者: 戲弄 時間: 2025-3-21 17:51
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease影響因子(影響力)
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease影響因子(影響力)學科排名
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease網絡公開度
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease網絡公開度學科排名
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease被引頻次
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease被引頻次學科排名
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease年度引用
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease年度引用學科排名
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease讀者反饋
書目名稱Computational Modeling of Drugs Against Alzheimer’s Disease讀者反饋學科排名
作者: Indolent 時間: 2025-3-21 20:20
Recent Advances in Computational Modeling of BACE1 Inhibitors as Anti-Alzheimer Agentsdefined by progressive neuronal death and synaptic loss in the human brain and can be brought on by both genetic and environmental risk factors. The beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is the major beta secretase for the generation of amyloid-β peptides in the neurons作者: 租約 時間: 2025-3-22 01:50 作者: 枯燥 時間: 2025-3-22 07:07 作者: certitude 時間: 2025-3-22 09:52
Computer-Assisted Drug Design: A Toolbox for Novel Tau Kinase Inhibitors and Its Implications in Alzies in proteins, responsible for regulating normal cellular metabolism. However, a slight imbalance in the kinase signaling pathways leads to hyperphosphorylation of the residues, resulting in pathological disorders eventually leading to neurodegenerative diseases. Therefore, the design of scaffolds作者: 恭維 時間: 2025-3-22 14:52
Computational Modeling Approaches in Search of Anti-Alzheimer’s Disease Agents: Case Studies of Phos messengers: cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Due to the high expression of various PDE subfamilies in the human brain, PDE inhibition has a substantial impact on neurodegenerative diseases by controlling the level of cAMP or cGMP. In this regard, seve作者: 恭維 時間: 2025-3-22 17:17
Recent Advances in Computational Modeling of Multi-targeting Inhibitors as Anti-Alzheimer Agentsnges. It is highly prevalent in the elderly, with a constantly growing number of new cases worldwide. In affluent nations with aging populations, AD has been a major source of economic and social problems. As a result, the discovery of novel treatment methods for this disease is now crucial. With ad作者: Priapism 時間: 2025-3-22 22:18 作者: 灌輸 時間: 2025-3-23 02:52
Computational Modeling of DYRK1A Inhibitors as Potential Anti-Alzheimer Agents, especially Alzheimer’s disease (AD). In this chapter, different ligand-based and structure-based computational approaches were explored to develop a workflow for the selection of potential candidates as inhibitors of DYRK1A. The NuBBE database—comprising different compounds from the Brazilian biod作者: 捕鯨魚叉 時間: 2025-3-23 05:54 作者: 假 時間: 2025-3-23 10:47 作者: PALMY 時間: 2025-3-23 17:27 作者: 修飾 時間: 2025-3-23 22:05 作者: 憎惡 時間: 2025-3-23 22:40
Network Pharmacology for Drug Repositioning in Anti-Alzheimer’s Drug Developmenture rather than symptom management. Alternative strategies, such as repositioning existing drugs to treat AD, have been increasingly applied recently due to the sluggish pace and rising failure rate of traditional drug discovery. Reevaluating existing drugs for a new indication is known as “drug rep作者: 妨礙議事 時間: 2025-3-24 04:13
Anton Neschadim,Jeffrey A. Medinr cure the disease. Presently, targeted drug delivery to the central nervous system (CNS) for AD therapy is hampered by the difficulties posed by blood-brain interfaces surrounding the CNS, reducing therapeutic bioavailability. Among innovative ways to overcome these restrictions and successfully de作者: Brittle 時間: 2025-3-24 08:31 作者: 不舒服 時間: 2025-3-24 14:21
Carol Swetlik B.A.,Kathleen N. Franco M.D.ng concepts of Alzheimer’s disease are discussed, along with the general structural aspect of kinases. Secondly, the discussion moves toward an overview of other groups’ reported inhibitors of the CMGC family of kinases, namely, DYRK1A, CLK1, GSK3β, and CDK5. Finally, our effort lied to modulate how作者: Substance 時間: 2025-3-24 15:27 作者: LURE 時間: 2025-3-24 20:31
An Overview of Indigenous Suicidel drugs. Recently, this approach has played an increasingly important role in the search for new medications to treat AD. Computational modeling helps conserve experimental resources and dramatically accelerates advances in drug research. In this chapter, various computational modeling methods utili作者: 臭了生氣 時間: 2025-3-24 23:25 作者: intention 時間: 2025-3-25 07:08
Suicide by Proxy in Early Modern Germany may lay foundations of neurodegeneration long before clinical neuropathology manifests..It is challenging to intuit which of the many peripheral ailments may be relevant to downstream neuropathology. This chapter thus offers information-based suggestions for how to pursue novel target perception, o作者: 全部 時間: 2025-3-25 08:19
https://doi.org/10.1007/978-3-031-25244-0changing them without compromising the essential molecular details. Network pharmacology guides and assists drug repositioning by identifying new drug targets, disease mechanisms, multi-target drugs, drug combinations, and adverse drug reactions through the analysis and molecular visualization of mu作者: fulcrum 時間: 2025-3-25 15:32 作者: maroon 時間: 2025-3-25 17:55
Computational Modeling of Drugs Against Alzheimer’s Disease作者: dominant 時間: 2025-3-25 21:55 作者: sclera 時間: 2025-3-26 01:02 作者: 失敗主義者 時間: 2025-3-26 04:43
Recent Progress in the Treatment Strategies for Alzheimer’s Diseaser cure the disease. Presently, targeted drug delivery to the central nervous system (CNS) for AD therapy is hampered by the difficulties posed by blood-brain interfaces surrounding the CNS, reducing therapeutic bioavailability. Among innovative ways to overcome these restrictions and successfully de作者: 圓錐 時間: 2025-3-26 08:40 作者: reserve 時間: 2025-3-26 16:15
Computer-Assisted Drug Design: A Toolbox for Novel Tau Kinase Inhibitors and Its Implications in Alzng concepts of Alzheimer’s disease are discussed, along with the general structural aspect of kinases. Secondly, the discussion moves toward an overview of other groups’ reported inhibitors of the CMGC family of kinases, namely, DYRK1A, CLK1, GSK3β, and CDK5. Finally, our effort lied to modulate how作者: 輪流 時間: 2025-3-26 20:00
Computational Modeling Approaches in Search of Anti-Alzheimer’s Disease Agents: Case Studies of Phos significant cognitive improvement effects in preclinical investigations and more than 33 of them have been subjected to clinical trials. In the search for novel drugs, computational drug design methods are now essential. Computational approaches, whether structure-based (protein structure predictio作者: Lumbar-Stenosis 時間: 2025-3-26 22:34
Recent Advances in Computational Modeling of Multi-targeting Inhibitors as Anti-Alzheimer Agentsl drugs. Recently, this approach has played an increasingly important role in the search for new medications to treat AD. Computational modeling helps conserve experimental resources and dramatically accelerates advances in drug research. In this chapter, various computational modeling methods utili作者: LIEN 時間: 2025-3-27 04:14 作者: mighty 時間: 2025-3-27 05:35
Basic Information Science Methods for Insight into Neurodegenerative Pathogenesis may lay foundations of neurodegeneration long before clinical neuropathology manifests..It is challenging to intuit which of the many peripheral ailments may be relevant to downstream neuropathology. This chapter thus offers information-based suggestions for how to pursue novel target perception, o作者: FORGO 時間: 2025-3-27 11:32
Network Pharmacology for Drug Repositioning in Anti-Alzheimer’s Drug Developmentchanging them without compromising the essential molecular details. Network pharmacology guides and assists drug repositioning by identifying new drug targets, disease mechanisms, multi-target drugs, drug combinations, and adverse drug reactions through the analysis and molecular visualization of mu作者: colloquial 時間: 2025-3-27 16:19
Kunal RoyIncludes cutting-edge methods and protocols.Provides step-by-step detail essential for reproducible results.Contains key notes and implementation advice from the experts作者: RALES 時間: 2025-3-27 21:22 作者: 不規(guī)則 時間: 2025-3-27 22:01
https://doi.org/10.1007/978-1-0716-3311-3drug development; acetylcholinesterase; butyrylcholinesterase; NMDA receptor; BACE-1 inhibitors作者: receptors 時間: 2025-3-28 02:36
978-1-0716-3313-7The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Busines作者: 不能根除 時間: 2025-3-28 08:39 作者: 狂亂 時間: 2025-3-28 10:43
Anton Neschadim,Jeffrey A. Medinpairments found are presumed to be the result of synapse disruption and neurochemical deficits. Several neurochemical abnormalities have been found throughout progressive aging, and these have been connected to cognitive dysfunction seen in the sporadic stage of AD. There are various hypotheses expl作者: Psychogenic 時間: 2025-3-28 15:57
Carol Swetlik B.A.,Kathleen N. Franco M.D.defined by progressive neuronal death and synaptic loss in the human brain and can be brought on by both genetic and environmental risk factors. The beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is the major beta secretase for the generation of amyloid-β peptides in the neurons作者: liposuction 時間: 2025-3-28 22:23
Farah Munir,Sarah Nagle-Yang,Cathleen Cernyent of this ailment. Despite several hurdles have been overcome and several BACE-1 inhibitors progressed to clinical trials, none has reached the market until now. The synergy of ligand- and structure-based molecular modeling tools proved essential to gain a deeper understanding of BACE-1 conformati作者: dilute 時間: 2025-3-29 00:20
Farah Munir,Sarah Nagle-Yang,Cathleen Cerny, and behavioral changes. Being the most common form of senile dementia, AD can be characterized by the presence of two types of neuropathological hallmarks: neurofibrillary tangles (NFTs) and senile plaques (SP). The phosphorylation of tau is controlled and regulated by a group of kinase and phosph作者: 杠桿支點 時間: 2025-3-29 03:07 作者: Override 時間: 2025-3-29 09:09 作者: Blanch 時間: 2025-3-29 11:43 作者: 埋葬 時間: 2025-3-29 18:59
Ad J. F. M. Kerkhof,Brian L. Misharaand tau imaging agents can detect early AD pathological processes and subsequent neurodegeneration. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are efficient imaging techniques for the in vivo detection of Alzheimer’s disease pathologies. In the current 作者: 果核 時間: 2025-3-29 20:23 作者: 矛盾 時間: 2025-3-30 01:01
Protective Factors in Suicidal Behavior huge economic as well as societal burden. The markers of oxidative stress have been noted early in AD, which highlight the likely participation of reactive oxygen species (ROS) in the cascade of events that lead to neuronal dysfunction. The mitochondrial enzyme monoamine oxidase (MAO) helps in the 作者: 把手 時間: 2025-3-30 04:23 作者: Control-Group 時間: 2025-3-30 11:00
Suicide and Early Christian Values,myloidogenic cyclization of N-terminal glutaminyl of Aβ to pyroglutamate is catalyzed by a metalloenzyme, glutaminyl cyclase (QC). Clinical findings indicated that the pyroglutamate Aβ (pGlu-Aβ) is more neurotoxic, resistant to hydrolysis, and more soluble and have more tendency to form plaques. The作者: 緩和 時間: 2025-3-30 14:50 作者: membrane 時間: 2025-3-30 18:12 作者: Mundane 時間: 2025-3-30 23:09
Modeling of BACE-1 Inhibitors as Anti-Alzheimer’s Agentsonal flexibility, its allosteric regulation, as well as identify novel molecular scaffolds that explore cryptic and allosteric sites in BACE-1 or have improved BACE-1/BACE-2 selectivity profile. This chapter showcases recent contributions to the above achievements and highlights the challenges ahead.作者: novelty 時間: 2025-3-31 03:32
Carol Swetlik B.A.,Kathleen N. Franco M.D.s of one of the principal pharmaceutical routes. Using computer-aided drug design, inhibitors for the BACE1 biomolecular target connected to Alzheimer’s disease have been effectively created. In this chapter, the recent developments in the computational modeling search of novel BACE1 inhibitors are discussed.
